| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prader-Willi Syndrome | 18 | 2024 | 67 | 5.930 |
Why?
|
| Bariatric Surgery | 5 | 2022 | 116 | 1.550 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 10 | 2024 | 389 | 1.520 |
Why?
|
| Gastrectomy | 4 | 2021 | 90 | 1.300 |
Why?
|
| Fatty Liver | 6 | 2015 | 178 | 1.060 |
Why?
|
| Pediatric Obesity | 5 | 2022 | 384 | 1.020 |
Why?
|
| Obesity, Morbid | 5 | 2021 | 185 | 0.940 |
Why?
|
| Larynx | 1 | 2024 | 69 | 0.850 |
Why?
|
| Muscle Hypotonia | 1 | 2024 | 185 | 0.840 |
Why?
|
| Obesity | 10 | 2020 | 2230 | 0.790 |
Why?
|
| Bardet-Biedl Syndrome | 1 | 2022 | 38 | 0.790 |
Why?
|
| Hypothalamic Diseases | 1 | 2022 | 37 | 0.760 |
Why?
|
| Gastroenterology | 4 | 2020 | 191 | 0.760 |
Why?
|
| Choline | 2 | 2012 | 54 | 0.750 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2020 | 223 | 0.720 |
Why?
|
| Diet, High-Protein Low-Carbohydrate | 1 | 2020 | 1 | 0.710 |
Why?
|
| Biological Clocks | 1 | 2020 | 28 | 0.690 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2020 | 64 | 0.680 |
Why?
|
| Hypertension, Portal | 1 | 2020 | 78 | 0.670 |
Why?
|
| Cecal Diseases | 1 | 2019 | 6 | 0.670 |
Why?
|
| Child | 43 | 2024 | 24247 | 0.660 |
Why?
|
| Hyperphagia | 5 | 2022 | 46 | 0.660 |
Why?
|
| Cysts | 1 | 2019 | 100 | 0.620 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2020 | 313 | 0.620 |
Why?
|
| Sleep Wake Disorders | 1 | 2020 | 177 | 0.590 |
Why?
|
| Rectum | 1 | 2018 | 97 | 0.580 |
Why?
|
| Self-Injurious Behavior | 1 | 2018 | 64 | 0.570 |
Why?
|
| Gastroesophageal Reflux | 2 | 2020 | 290 | 0.570 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2020 | 205 | 0.570 |
Why?
|
| Pediatrics | 5 | 2022 | 1142 | 0.550 |
Why?
|
| Child Nutrition Sciences | 1 | 2016 | 19 | 0.540 |
Why?
|
| Ascites | 4 | 2022 | 87 | 0.530 |
Why?
|
| Sleep Apnea Syndromes | 2 | 2015 | 74 | 0.530 |
Why?
|
| Humans | 78 | 2024 | 123180 | 0.530 |
Why?
|
| Duodenum | 3 | 2020 | 97 | 0.510 |
Why?
|
| Awards and Prizes | 1 | 2016 | 63 | 0.500 |
Why?
|
| Choline Deficiency | 2 | 2012 | 4 | 0.500 |
Why?
|
| Adolescent | 36 | 2024 | 19111 | 0.490 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2015 | 44 | 0.470 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2015 | 58 | 0.460 |
Why?
|
| Metabolic Diseases | 2 | 2015 | 130 | 0.440 |
Why?
|
| Infant | 20 | 2024 | 12371 | 0.410 |
Why?
|
| Biliopancreatic Diversion | 1 | 2012 | 4 | 0.400 |
Why?
|
| Dyslipidemias | 1 | 2015 | 229 | 0.400 |
Why?
|
| Male | 41 | 2024 | 60173 | 0.390 |
Why?
|
| Female | 45 | 2024 | 65562 | 0.390 |
Why?
|
| Child, Preschool | 23 | 2024 | 13904 | 0.380 |
Why?
|
| Child Health Services | 1 | 2012 | 86 | 0.370 |
Why?
|
| Quality of Life | 1 | 2020 | 1924 | 0.360 |
Why?
|
| Diet | 4 | 2013 | 1130 | 0.360 |
Why?
|
| Giant Cells | 1 | 2010 | 34 | 0.360 |
Why?
|
| Bile Ducts, Intrahepatic | 2 | 2010 | 95 | 0.360 |
Why?
|
| Cholestasis, Intrahepatic | 2 | 2010 | 58 | 0.350 |
Why?
|
| Intestinal Diseases | 1 | 2011 | 83 | 0.350 |
Why?
|
| Hepatitis | 1 | 2010 | 59 | 0.340 |
Why?
|
| Severity of Illness Index | 8 | 2024 | 2850 | 0.340 |
Why?
|
| Food Hypersensitivity | 2 | 2015 | 151 | 0.340 |
Why?
|
| Gastric Balloon | 1 | 2008 | 2 | 0.320 |
Why?
|
| Feeding and Eating Disorders | 2 | 2012 | 70 | 0.310 |
Why?
|
| Biopsy | 6 | 2020 | 1236 | 0.310 |
Why?
|
| Weight Loss | 4 | 2022 | 479 | 0.300 |
Why?
|
| Laparoscopy | 2 | 2016 | 501 | 0.300 |
Why?
|
| Stomach Rupture | 1 | 2007 | 3 | 0.290 |
Why?
|
| Necrosis | 2 | 2007 | 205 | 0.290 |
Why?
|
| Protein-Energy Malnutrition | 1 | 2008 | 76 | 0.290 |
Why?
|
| Dietary Supplements | 1 | 2011 | 472 | 0.290 |
Why?
|
| Liver Diseases | 4 | 2017 | 363 | 0.280 |
Why?
|
| Intestines | 1 | 2011 | 570 | 0.280 |
Why?
|
| Nutrition Assessment | 4 | 2023 | 133 | 0.280 |
Why?
|
| Nutritional Status | 4 | 2020 | 305 | 0.270 |
Why?
|
| Hypertension | 1 | 2015 | 1286 | 0.270 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2020 | 1231 | 0.270 |
Why?
|
| Liver | 5 | 2015 | 1736 | 0.260 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2007 | 186 | 0.260 |
Why?
|
| Alanine Transaminase | 4 | 2020 | 150 | 0.260 |
Why?
|
| Bile Duct Neoplasms | 1 | 2007 | 109 | 0.260 |
Why?
|
| Cholangiocarcinoma | 1 | 2007 | 107 | 0.260 |
Why?
|
| Hepatocytes | 2 | 2010 | 225 | 0.250 |
Why?
|
| Body Mass Index | 6 | 2022 | 1548 | 0.250 |
Why?
|
| Age Factors | 8 | 2020 | 2799 | 0.250 |
Why?
|
| Airway Obstruction | 1 | 2007 | 164 | 0.240 |
Why?
|
| Aging | 1 | 2012 | 1176 | 0.240 |
Why?
|
| Gastric Bypass | 2 | 2021 | 70 | 0.240 |
Why?
|
| Retrospective Studies | 15 | 2022 | 16062 | 0.240 |
Why?
|
| Pancreatitis | 2 | 2017 | 129 | 0.230 |
Why?
|
| Environmental Pollutants | 1 | 2024 | 68 | 0.220 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2024 | 52 | 0.220 |
Why?
|
| Neoplasms | 2 | 2017 | 2756 | 0.220 |
Why?
|
| Child Nutritional Physiological Phenomena | 2 | 2015 | 175 | 0.220 |
Why?
|
| Nutritional Sciences | 2 | 2014 | 75 | 0.210 |
Why?
|
| Deglutition Disorders | 1 | 2024 | 126 | 0.200 |
Why?
|
| Education, Medical, Continuing | 2 | 2014 | 138 | 0.200 |
Why?
|
| Cataplexy | 1 | 2022 | 1 | 0.200 |
Why?
|
| North America | 4 | 2016 | 239 | 0.200 |
Why?
|
| Narcolepsy | 1 | 2022 | 6 | 0.200 |
Why?
|
| Hydrothorax | 1 | 2022 | 11 | 0.200 |
Why?
|
| Enteral Nutrition | 1 | 2024 | 250 | 0.190 |
Why?
|
| Adult | 14 | 2024 | 29032 | 0.190 |
Why?
|
| Body Weight | 3 | 2023 | 1000 | 0.190 |
Why?
|
| Hepatitis E | 1 | 2021 | 5 | 0.180 |
Why?
|
| Congenital Abnormalities | 1 | 2024 | 255 | 0.180 |
Why?
|
| Disaccharidases | 1 | 2020 | 14 | 0.180 |
Why?
|
| Ascitic Fluid | 1 | 2020 | 30 | 0.180 |
Why?
|
| Lactase | 1 | 2020 | 41 | 0.180 |
Why?
|
| Ambulatory Care Facilities | 1 | 2023 | 229 | 0.180 |
Why?
|
| Serum Albumin | 1 | 2020 | 107 | 0.180 |
Why?
|
| Sucrase-Isomaltase Complex | 1 | 2020 | 19 | 0.180 |
Why?
|
| Liver Cirrhosis | 4 | 2022 | 824 | 0.170 |
Why?
|
| Healthy Lifestyle | 1 | 2020 | 31 | 0.170 |
Why?
|
| Vitamin E | 2 | 2011 | 64 | 0.170 |
Why?
|
| Family Characteristics | 1 | 2020 | 77 | 0.170 |
Why?
|
| Hepatic Encephalopathy | 1 | 2021 | 74 | 0.170 |
Why?
|
| Carbohydrate Metabolism, Inborn Errors | 1 | 2020 | 36 | 0.170 |
Why?
|
| Insulin | 4 | 2001 | 1200 | 0.170 |
Why?
|
| Biopsy, Needle | 1 | 2000 | 229 | 0.170 |
Why?
|
| Hepatomegaly | 1 | 1999 | 21 | 0.170 |
Why?
|
| Migraine Disorders | 1 | 2021 | 64 | 0.170 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2020 | 117 | 0.170 |
Why?
|
| Cecum | 1 | 2019 | 27 | 0.170 |
Why?
|
| Exercise | 3 | 2022 | 816 | 0.170 |
Why?
|
| DNA-Binding Proteins | 4 | 2001 | 2055 | 0.160 |
Why?
|
| Risk Reduction Behavior | 1 | 2020 | 135 | 0.160 |
Why?
|
| Fibrosis | 2 | 2012 | 429 | 0.160 |
Why?
|
| Cystic Fibrosis | 2 | 2014 | 257 | 0.160 |
Why?
|
| Mental Health Services | 1 | 2022 | 247 | 0.160 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 1 | 4 | 2001 | 20 | 0.160 |
Why?
|
| Endpoint Determination | 1 | 2018 | 53 | 0.150 |
Why?
|
| Metformin | 2 | 2011 | 147 | 0.150 |
Why?
|
| Adolescent Nutritional Physiological Phenomena | 2 | 2015 | 33 | 0.150 |
Why?
|
| Gastrointestinal Tract | 1 | 2020 | 208 | 0.150 |
Why?
|
| Circadian Rhythm | 1 | 2020 | 268 | 0.150 |
Why?
|
| Ultrasonography | 2 | 2019 | 940 | 0.150 |
Why?
|
| Interdisciplinary Communication | 1 | 2019 | 134 | 0.150 |
Why?
|
| Transcription Factors | 4 | 2001 | 2587 | 0.150 |
Why?
|
| Hospitalization | 3 | 2021 | 1739 | 0.150 |
Why?
|
| Cyclohexanes | 1 | 2017 | 8 | 0.150 |
Why?
|
| Aminopeptidases | 1 | 2017 | 19 | 0.140 |
Why?
|
| Epoxy Compounds | 1 | 2017 | 18 | 0.140 |
Why?
|
| Appetite Depressants | 1 | 2017 | 22 | 0.140 |
Why?
|
| Cinnamates | 1 | 2017 | 15 | 0.140 |
Why?
|
| Sesquiterpenes | 1 | 2017 | 22 | 0.140 |
Why?
|
| Patient Preference | 1 | 2018 | 115 | 0.140 |
Why?
|
| Neutropenia | 2 | 2004 | 202 | 0.140 |
Why?
|
| Registries | 1 | 2024 | 1394 | 0.140 |
Why?
|
| Colonoscopy | 1 | 2019 | 239 | 0.140 |
Why?
|
| Sleep | 1 | 2020 | 348 | 0.140 |
Why?
|
| Quality Improvement | 1 | 2023 | 626 | 0.140 |
Why?
|
| Mutation | 5 | 2007 | 5767 | 0.140 |
Why?
|
| Protease Inhibitors | 1 | 2017 | 93 | 0.140 |
Why?
|
| Attitude of Health Personnel | 3 | 2014 | 642 | 0.140 |
Why?
|
| Societies, Scientific | 1 | 2016 | 26 | 0.140 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2020 | 203 | 0.140 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 1306 | 0.140 |
Why?
|
| Hypoglycemic Agents | 2 | 2011 | 426 | 0.140 |
Why?
|
| Nephrotic Syndrome | 1 | 2017 | 47 | 0.130 |
Why?
|
| Vomiting | 2 | 2007 | 115 | 0.130 |
Why?
|
| Medically Underserved Area | 1 | 2016 | 93 | 0.130 |
Why?
|
| Feeding and Eating Disorders of Childhood | 1 | 2015 | 14 | 0.120 |
Why?
|
| History, 21st Century | 1 | 2016 | 269 | 0.120 |
Why?
|
| Surveys and Questionnaires | 4 | 2020 | 3670 | 0.120 |
Why?
|
| United States | 6 | 2021 | 10660 | 0.120 |
Why?
|
| Disease Management | 1 | 2019 | 516 | 0.120 |
Why?
|
| Glycoproteins | 1 | 2017 | 369 | 0.120 |
Why?
|
| Vulnerable Populations | 1 | 2016 | 140 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 4 | 2001 | 1339 | 0.120 |
Why?
|
| Short Bowel Syndrome | 2 | 2014 | 59 | 0.120 |
Why?
|
| Young Adult | 6 | 2024 | 8864 | 0.120 |
Why?
|
| Infant Formula | 1 | 2015 | 98 | 0.120 |
Why?
|
| Child Nutrition Disorders | 1 | 2015 | 76 | 0.120 |
Why?
|
| Morbidity | 2 | 2021 | 241 | 0.110 |
Why?
|
| Leadership | 1 | 2016 | 230 | 0.110 |
Why?
|
| Infant Nutritional Physiological Phenomena | 1 | 2015 | 192 | 0.110 |
Why?
|
| Vitamin D Deficiency | 1 | 2015 | 71 | 0.110 |
Why?
|
| Craniopharyngioma | 1 | 2014 | 33 | 0.110 |
Why?
|
| Nutritional Support | 1 | 2014 | 51 | 0.110 |
Why?
|
| Cross-Sectional Studies | 4 | 2022 | 3375 | 0.110 |
Why?
|
| Teicoplanin | 1 | 1993 | 3 | 0.110 |
Why?
|
| Caregivers | 1 | 2018 | 572 | 0.110 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 1876 | 0.100 |
Why?
|
| Professional Role | 1 | 2013 | 57 | 0.100 |
Why?
|
| Infant, Newborn | 6 | 2021 | 8115 | 0.100 |
Why?
|
| Administration, Oral | 3 | 2011 | 667 | 0.100 |
Why?
|
| Malnutrition | 1 | 2015 | 197 | 0.100 |
Why?
|
| Prevalence | 5 | 2020 | 2397 | 0.100 |
Why?
|
| Research | 1 | 2014 | 263 | 0.100 |
Why?
|
| Program Evaluation | 1 | 2014 | 449 | 0.100 |
Why?
|
| Dietetics | 1 | 2012 | 19 | 0.100 |
Why?
|
| Melena | 1 | 2011 | 5 | 0.100 |
Why?
|
| Human Growth Hormone | 2 | 2011 | 74 | 0.100 |
Why?
|
| Puberty | 1 | 2012 | 94 | 0.090 |
Why?
|
| Referral and Consultation | 1 | 2015 | 529 | 0.090 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2011 | 26 | 0.090 |
Why?
|
| Postmenopause | 1 | 2012 | 125 | 0.090 |
Why?
|
| Growth Charts | 1 | 2011 | 12 | 0.090 |
Why?
|
| Arteriovenous Malformations | 1 | 2011 | 46 | 0.090 |
Why?
|
| Nutritional Requirements | 1 | 2012 | 177 | 0.090 |
Why?
|
| Digestive System Diseases | 1 | 2011 | 17 | 0.090 |
Why?
|
| Hematopoiesis, Extramedullary | 1 | 2010 | 9 | 0.090 |
Why?
|
| Hypopituitarism | 1 | 2010 | 15 | 0.090 |
Why?
|
| Liver Transplantation | 4 | 2000 | 1022 | 0.090 |
Why?
|
| Treatment Outcome | 3 | 2022 | 12142 | 0.090 |
Why?
|
| Societies, Medical | 4 | 2020 | 676 | 0.090 |
Why?
|
| Cyclosporine | 4 | 1998 | 146 | 0.090 |
Why?
|
| Fever | 1 | 1993 | 296 | 0.090 |
Why?
|
| Alagille Syndrome | 1 | 2010 | 47 | 0.090 |
Why?
|
| Parenteral Nutrition | 1 | 2011 | 183 | 0.080 |
Why?
|
| Length of Stay | 4 | 2021 | 1288 | 0.080 |
Why?
|
| Life Style | 2 | 2013 | 402 | 0.080 |
Why?
|
| Cross Infection | 1 | 1993 | 330 | 0.080 |
Why?
|
| Cytomegalovirus Infections | 1 | 2011 | 217 | 0.080 |
Why?
|
| Pneumonia | 1 | 1993 | 325 | 0.080 |
Why?
|
| Colon | 1 | 2011 | 352 | 0.080 |
Why?
|
| Colitis, Ulcerative | 1 | 2011 | 207 | 0.080 |
Why?
|
| Antioxidants | 1 | 2011 | 338 | 0.080 |
Why?
|
| Prospective Studies | 4 | 2020 | 6029 | 0.080 |
Why?
|
| Jejunoileal Bypass | 1 | 2008 | 4 | 0.080 |
Why?
|
| Vagotomy | 1 | 2008 | 10 | 0.070 |
Why?
|
| MEDLINE | 1 | 2008 | 20 | 0.070 |
Why?
|
| Gastroplasty | 1 | 2008 | 10 | 0.070 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2008 | 32 | 0.070 |
Why?
|
| Gastric Dilatation | 1 | 2007 | 3 | 0.070 |
Why?
|
| Biliary Atresia | 1 | 2010 | 186 | 0.070 |
Why?
|
| Television | 1 | 2008 | 71 | 0.070 |
Why?
|
| Middle Aged | 4 | 2018 | 26015 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2008 | 159 | 0.070 |
Why?
|
| Pilot Projects | 1 | 2011 | 1389 | 0.070 |
Why?
|
| Disease Progression | 2 | 2024 | 2028 | 0.070 |
Why?
|
| Immunosuppressive Agents | 3 | 1998 | 645 | 0.070 |
Why?
|
| Clinical Competence | 1 | 2013 | 973 | 0.060 |
Why?
|
| Baltimore | 2 | 2015 | 13 | 0.060 |
Why?
|
| Body Composition | 1 | 2008 | 513 | 0.060 |
Why?
|
| Famotidine | 1 | 2005 | 9 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2012 | 4703 | 0.060 |
Why?
|
| Cause of Death | 1 | 2007 | 463 | 0.060 |
Why?
|
| Double-Blind Method | 3 | 2017 | 1585 | 0.060 |
Why?
|
| Health Education | 2 | 2020 | 225 | 0.060 |
Why?
|
| Abdominal Pain | 1 | 2007 | 307 | 0.060 |
Why?
|
| Halogenated Diphenyl Ethers | 1 | 2024 | 8 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 3 | 2001 | 1061 | 0.060 |
Why?
|
| Histamine H2 Antagonists | 1 | 2005 | 49 | 0.060 |
Why?
|
| Acute Kidney Injury | 1 | 2011 | 614 | 0.060 |
Why?
|
| Clostridium perfringens | 1 | 2004 | 7 | 0.060 |
Why?
|
| Forkhead Box Protein O1 | 2 | 2001 | 95 | 0.060 |
Why?
|
| Intestinal Fistula | 1 | 2004 | 28 | 0.060 |
Why?
|
| Sugars | 1 | 2023 | 15 | 0.060 |
Why?
|
| Heart Failure | 1 | 2017 | 2129 | 0.060 |
Why?
|
| Enteritis | 1 | 2004 | 54 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 1074 | 0.050 |
Why?
|
| Gastrostomy | 1 | 2024 | 84 | 0.050 |
Why?
|
| Aged | 3 | 2021 | 19108 | 0.050 |
Why?
|
| Systems Analysis | 1 | 2023 | 14 | 0.050 |
Why?
|
| Blood Pressure | 1 | 2008 | 1325 | 0.050 |
Why?
|
| Environmental Exposure | 1 | 2024 | 217 | 0.050 |
Why?
|
| Transfection | 2 | 2001 | 1068 | 0.050 |
Why?
|
| Forkhead Transcription Factors | 2 | 2001 | 367 | 0.050 |
Why?
|
| Caustics | 1 | 2001 | 5 | 0.050 |
Why?
|
| Binding, Competitive | 1 | 2001 | 180 | 0.050 |
Why?
|
| Esophageal Stenosis | 1 | 2001 | 44 | 0.050 |
Why?
|
| Gastroscopy | 1 | 2001 | 102 | 0.050 |
Why?
|
| Esophageal Achalasia | 1 | 2001 | 37 | 0.050 |
Why?
|
| Luminescent Proteins | 1 | 2001 | 157 | 0.050 |
Why?
|
| Hemorrhage | 2 | 2004 | 458 | 0.050 |
Why?
|
| Reference Values | 2 | 2013 | 697 | 0.050 |
Why?
|
| Equipment Safety | 1 | 2000 | 37 | 0.050 |
Why?
|
| Blood Coagulation Tests | 1 | 2000 | 60 | 0.040 |
Why?
|
| Needles | 1 | 2000 | 51 | 0.040 |
Why?
|
| Esophagoscopy | 1 | 2001 | 156 | 0.040 |
Why?
|
| Hematocrit | 1 | 2000 | 110 | 0.040 |
Why?
|
| Risk Factors | 3 | 2020 | 10031 | 0.040 |
Why?
|
| High Mobility Group Proteins | 2 | 1997 | 32 | 0.040 |
Why?
|
| Plasmids | 1 | 2001 | 511 | 0.040 |
Why?
|
| Lipids | 1 | 2023 | 514 | 0.040 |
Why?
|
| Aspartate Aminotransferases | 1 | 2020 | 76 | 0.040 |
Why?
|
| Clostridium Infections | 1 | 2004 | 241 | 0.040 |
Why?
|
| Microscopy, Fluorescence | 1 | 2001 | 330 | 0.040 |
Why?
|
| Green Fluorescent Proteins | 1 | 2001 | 394 | 0.040 |
Why?
|
| France | 2 | 2006 | 78 | 0.040 |
Why?
|
| Radiography, Abdominal | 1 | 1999 | 47 | 0.040 |
Why?
|
| Universities | 1 | 2020 | 128 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2017 | 1681 | 0.040 |
Why?
|
| Genotype | 2 | 2020 | 2533 | 0.040 |
Why?
|
| Blotting, Western | 1 | 2001 | 1100 | 0.040 |
Why?
|
| Hemoglobins | 1 | 2000 | 301 | 0.040 |
Why?
|
| Comorbidity | 2 | 2015 | 1497 | 0.040 |
Why?
|
| Overweight | 1 | 2022 | 358 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2006 | 1258 | 0.040 |
Why?
|
| Biomarkers | 2 | 2020 | 2943 | 0.040 |
Why?
|
| Binding Sites | 1 | 2001 | 1292 | 0.040 |
Why?
|
| Heterozygote | 1 | 2020 | 678 | 0.040 |
Why?
|
| Methionyl Aminopeptidases | 1 | 2017 | 2 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2021 | 365 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2001 | 1610 | 0.040 |
Why?
|
| Time Factors | 2 | 2020 | 6221 | 0.040 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2017 | 16 | 0.040 |
Why?
|
| Blood Glucose | 2 | 2020 | 1119 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2017 | 57 | 0.040 |
Why?
|
| Budd-Chiari Syndrome | 1 | 2017 | 7 | 0.030 |
Why?
|
| Maryland | 1 | 2017 | 28 | 0.030 |
Why?
|
| Inpatients | 1 | 2021 | 492 | 0.030 |
Why?
|
| Rare Diseases | 1 | 2018 | 185 | 0.030 |
Why?
|
| Seizures | 1 | 2022 | 874 | 0.030 |
Why?
|
| Anxiety Disorders | 1 | 2022 | 677 | 0.030 |
Why?
|
| Thailand | 1 | 2015 | 34 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2008 | 3015 | 0.030 |
Why?
|
| Physical Examination | 1 | 2017 | 163 | 0.030 |
Why?
|
| Recommended Dietary Allowances | 1 | 2015 | 23 | 0.030 |
Why?
|
| Lactose | 1 | 2015 | 54 | 0.030 |
Why?
|
| Venous Thrombosis | 1 | 2017 | 180 | 0.030 |
Why?
|
| 25-Hydroxyvitamin D 2 | 1 | 2015 | 6 | 0.030 |
Why?
|
| Calcifediol | 1 | 2015 | 13 | 0.030 |
Why?
|
| Micronutrients | 1 | 2015 | 67 | 0.030 |
Why?
|
| Milk Proteins | 1 | 2015 | 91 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2020 | 1172 | 0.030 |
Why?
|
| Academies and Institutes | 1 | 2015 | 83 | 0.030 |
Why?
|
| Dietary Carbohydrates | 1 | 2015 | 118 | 0.030 |
Why?
|
| Radiography | 1 | 2017 | 822 | 0.030 |
Why?
|
| Pregnancy | 2 | 2021 | 7146 | 0.030 |
Why?
|
| Health Personnel | 1 | 2019 | 493 | 0.030 |
Why?
|
| Satiety Response | 1 | 2014 | 32 | 0.030 |
Why?
|
| Hypertriglyceridemia | 1 | 2015 | 100 | 0.030 |
Why?
|
| Hospitals | 1 | 2017 | 393 | 0.030 |
Why?
|
| Nuclear Proteins | 2 | 1997 | 1268 | 0.030 |
Why?
|
| Dietary Fats | 1 | 2015 | 296 | 0.030 |
Why?
|
| Behavior, Addictive | 1 | 2014 | 59 | 0.030 |
Why?
|
| Age of Onset | 1 | 2015 | 581 | 0.030 |
Why?
|
| Maple Syrup Urine Disease | 1 | 1993 | 15 | 0.030 |
Why?
|
| Incidence | 1 | 2000 | 3045 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2019 | 828 | 0.030 |
Why?
|
| Energy Intake | 1 | 2015 | 489 | 0.030 |
Why?
|
| Brain Edema | 1 | 1993 | 69 | 0.030 |
Why?
|
| Anxiety | 1 | 2018 | 961 | 0.020 |
Why?
|
| Histocytochemistry | 1 | 2012 | 99 | 0.020 |
Why?
|
| Injections, Intravenous | 2 | 2005 | 252 | 0.020 |
Why?
|
| Acute Disease | 1 | 2015 | 1093 | 0.020 |
Why?
|
| Models, Animal | 1 | 2014 | 464 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1999 | 2056 | 0.020 |
Why?
|
| Eating | 1 | 2014 | 372 | 0.020 |
Why?
|
| Parents | 1 | 2018 | 1033 | 0.020 |
Why?
|
| Reproductive Health | 1 | 2012 | 44 | 0.020 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2014 | 381 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2020 | 2587 | 0.020 |
Why?
|
| Cephalometry | 1 | 2011 | 33 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2020 | 3327 | 0.020 |
Why?
|
| Nutrition Disorders | 1 | 2011 | 32 | 0.020 |
Why?
|
| Data Collection | 1 | 2013 | 384 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2014 | 1243 | 0.020 |
Why?
|
| Resuscitation | 1 | 1993 | 244 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 1993 | 458 | 0.020 |
Why?
|
| Body Height | 1 | 2011 | 210 | 0.020 |
Why?
|
| Health Behavior | 1 | 2013 | 382 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 2113 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2009 | 101 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2014 | 816 | 0.020 |
Why?
|
| Niacinamide | 1 | 1989 | 24 | 0.020 |
Why?
|
| Energy Metabolism | 1 | 2014 | 770 | 0.020 |
Why?
|
| Emulsions | 2 | 1998 | 65 | 0.020 |
Why?
|
| Consensus | 1 | 2012 | 608 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2013 | 1165 | 0.020 |
Why?
|
| Feeding Behavior | 1 | 2014 | 707 | 0.020 |
Why?
|
| Islets of Langerhans | 1 | 1989 | 173 | 0.020 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 1989 | 135 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 6375 | 0.020 |
Why?
|
| Curriculum | 1 | 2013 | 718 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2011 | 1386 | 0.020 |
Why?
|
| Sex Factors | 1 | 2011 | 1261 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2011 | 334 | 0.020 |
Why?
|
| Polysomnography | 1 | 2008 | 141 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2013 | 713 | 0.020 |
Why?
|
| HMGA1a Protein | 2 | 1997 | 4 | 0.020 |
Why?
|
| Autoimmune Diseases | 1 | 1989 | 250 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 5040 | 0.020 |
Why?
|
| Patient Selection | 1 | 2009 | 683 | 0.020 |
Why?
|
| Research Design | 1 | 2009 | 676 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2005 | 142 | 0.010 |
Why?
|
| Half-Life | 1 | 2005 | 156 | 0.010 |
Why?
|
| Biological Availability | 1 | 2005 | 128 | 0.010 |
Why?
|
| Inflammation | 1 | 2012 | 1403 | 0.010 |
Why?
|
| Leukocyte Elastase | 1 | 2004 | 19 | 0.010 |
Why?
|
| Phenotype | 1 | 2014 | 4226 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2005 | 314 | 0.010 |
Why?
|
| Survival Rate | 2 | 1998 | 2000 | 0.010 |
Why?
|
| Electroencephalography | 1 | 2008 | 857 | 0.010 |
Why?
|
| Burns, Chemical | 1 | 2001 | 29 | 0.010 |
Why?
|
| DNA | 2 | 1997 | 1588 | 0.010 |
Why?
|
| Immunoblotting | 1 | 1999 | 312 | 0.010 |
Why?
|
| Living Donors | 1 | 1998 | 112 | 0.010 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 1997 | 49 | 0.010 |
Why?
|
| Hospital Costs | 1 | 1998 | 177 | 0.010 |
Why?
|
| Oligonucleotides | 1 | 1997 | 88 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1998 | 537 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2001 | 2011 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1999 | 767 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 1998 | 501 | 0.010 |
Why?
|
| Leucine Zippers | 1 | 1995 | 16 | 0.010 |
Why?
|
| Deoxyribonuclease I | 1 | 1995 | 49 | 0.010 |
Why?
|
| Hepatocyte Nuclear Factor 3-beta | 1 | 1995 | 28 | 0.010 |
Why?
|
| Tissue Donors | 1 | 1998 | 496 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 1998 | 1139 | 0.010 |
Why?
|
| Protein Binding | 1 | 1997 | 1741 | 0.010 |
Why?
|
| Base Sequence | 1 | 1997 | 3091 | 0.010 |
Why?
|
| Pseudotumor Cerebri | 1 | 1993 | 58 | 0.010 |
Why?
|
| Leucine | 1 | 1993 | 309 | 0.010 |
Why?
|
| Rats, Inbred BB | 1 | 1989 | 5 | 0.010 |
Why?
|
| Deferoxamine | 1 | 1989 | 7 | 0.010 |
Why?
|
| NAD | 1 | 1989 | 48 | 0.000 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 1989 | 28 | 0.000 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 1997 | 938 | 0.000 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1989 | 151 | 0.000 |
Why?
|
| Hyperplasia | 1 | 1989 | 209 | 0.000 |
Why?
|
| Liver Neoplasms | 1 | 1997 | 1311 | 0.000 |
Why?
|
| DNA Damage | 1 | 1989 | 512 | 0.000 |
Why?
|
| Models, Biological | 1 | 1989 | 1442 | 0.000 |
Why?
|
| Rats | 1 | 1989 | 3651 | 0.000 |
Why?
|
| Animals | 1 | 1989 | 33798 | 0.000 |
Why?
|